The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 344:319-326 February 1, 2001 Number 5
NextNext

Vaccinations and the Risk of Relapse in Multiple Sclerosis
Christian Confavreux, M.D., Samy Suissa, Ph.D., Patricia Saddier, M.D., Ph.D., Valerie Bourdes, M.D., M.P.H., Sandra Vukusic, M.D., for The Vaccines in Multiple Sclerosis Study Group

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Gellin, B. G.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background There has been some concern that vaccination may precipitate the onset of multiple sclerosis or lead to relapses. Since the recent hepatitis B vaccination program in France, there have been new reports of an increased risk of active multiple sclerosis after vaccination.

Methods We conducted a case–crossover study to assess whether vaccinations increase the risk of relapse in multiple sclerosis. The subjects were patients included in the European Database for Multiple Sclerosis who had a relapse between 1993 and 1997. The index relapse was the first relapse confirmed by a visit to a neurologist and preceded by a relapse-free period of at least 12 months. Information on vaccinations was obtained in a standardized telephone interview and confirmed by means of medical records. Exposure to vaccination in the two-month risk period immediately preceding the relapse was compared with that in the four previous two-month control periods for the calculation of relative risks, which were estimated with the use of conditional logistic regression.

Results Of 643 patients with relapses of multiple sclerosis, 15 percent reported having been vaccinated during the preceding 12 months. The reports of 94 percent of these vaccinations were confirmed. Of all the patients, 2.3 percent had been vaccinated during the preceding two-month risk period as compared with 2.8 to 4.0 percent who were vaccinated during one or more of the four control periods. The relative risk of relapse associated with exposure to any vaccination during the previous two months was 0.71 (95 percent confidence interval, 0.40 to 1.26). There was no increase in the specific risk of relapse associated with tetanus, hepatitis B, or influenza vaccination (range of relative risks, 0.22 to 1.08). Analyses based on risk periods of one and three months yielded similar results.

Conclusions Vaccination does not appear to increase the short-term risk of relapse in multiple sclerosis.


Source Information

From the European Database for Multiple Sclerosis Coordinating Center and the Service de Neurologie A, Hôpital Neurologique, Lyons, France (C.C., V.B., S.V.); the Division of Clinical Epidemiology, Royal Victoria Hospital, and the Department of Epidemiology and Biostatistics, the Department of Medicine, and the McGill Pharmacoepidemiology Research Unit, McGill University, Montreal (S.S.); and the Department of Epidemiology, Aventis Pasteur, Lyons, France (P.S.).

Address reprint requests to Dr. Confavreux at the EDMUS Coordinating Center, Hôpital Neurologique, 59 blvd. Pinel, 69394 Lyons CEDEX 03, France.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.